Abstract 【Objective】To explore the clinical effect of hysterolaparoscopy combined with medication for ovulation induction in the treatment of patients with tubal infertility. 【Methods】 Sixty patients with tubal infertility treated in our hospital were selected as the study subjects. They were randomly divided into Group A(treated with hysterolaparoscopy combined with Urofollitrophin), Group B(treated with hysterolaparoscopy combined with letrozole), and Group C(treated with hysteroscopy) using a random number table method, with 20 cases in each group. Two groups of patients were compared in terms of ovarian function indicators, postoperative pregnancy time, pregnancy rate, miscarriage rate, delivery rate, and abnormal fetal rate.【Results】 After treatment, the levels of ovarian function indicators such as estradiol(E2), follicle stimulating hormone(FSH), and luteinizing hormone(LH) in groups A, B, and C were higher than before treatment(P<0.05); After treatment, the levels of LH, FSH, and E2 in Group A were significantly higher than those in Group B and Group C(P<0.05); After treatment, the levels of LH, FSH, and E2 in Group B were significantly higher than those in Group C(P<0.05). The pregnancy rates of Group A, Group B, and Group C were 85.00%, 75.00%, and 55.00%, respectively. The differences among the three groups were statistically significant(P<0.05). The postoperative conception time in Group A was shorter than that in Group B and Group C(P<0.05); The postoperative conception time in Group B was shorter than that in Group C(P<0.05). The abortion rates of Group A, Group B, and Group C were 5.88%, 6.67%, and 27.27%, respectively. The difference among the three groups was statistically significant(P<0.05); The delivery rates of Group A, Group B, and Group C were 94.12%, 93.33%, and 72.73%, respectively. The differences among the three groups were statistically significant(P<0.05); The rates of abnormal fetuses in Group A, Group B, and Group C were 0, 0, and 9.09%, respectively. There was no statistically significant difference among the three groups(P>0.05).【Conclusion】 The combination of Hysterolaparoscopy and medication for ovulation induction can effectively improve ovarian function, increase pregnancy and delivery rates, and reduce miscarriage rates in patients with tubal infertility. However, compared to letrozole treatment, the combination of hysteroscopy and urinary follicle stimulating hormone treatment is more effective and worthy of clinical promotion and application.
[1] 吴红艳,贾涔琳.宫腔镜下输卵管插管疏通术治疗输卵管梗阻性不孕症的临床疗效研究[J].浙江创伤外科,2022,27(6):1103-1104. [2] 唐璟,吴少君,孙鸿展.女性输卵管不孕患者IVF-ET治疗次数对胚胎移植结局影响[J].实用预防医学,2022,29(7):877. [3] 高颖花,马丽丽,周明慧.宫腔镜输卵管插管通液术治疗输卵管性不孕症疗效及对术后恢复、妊娠的影响[J].中国计划生育学杂志,2022,30(10):2218-2221. [4] LIU C,QIU H,HUANG R, et al. Therapeutic mechanism and clinical observation of traditional chinese medicine combined with interventional recanalization for tubal infertility[J].Evid Based Complement Alternat Med,2021,20(56):47-51. [5] 阙彦臻,罗秋英,潘丽华.宫腹腔镜手术联合中西医药物治疗对输卵管阻塞性不孕症患者的效果研究[J].深圳中西医结合杂志,2022,32(22):40-43. [6] 沈素娟,李素红,张翠枝.宫腹腔镜联合治疗输卵管性不孕症的效果及对患者输卵管通畅、妊娠情况的影响[J].临床医学研究与实践,2022,7(24):73-75. [7] LING H,LUO L P,DAI X G, et al. Fallopian tubal infertility: the result of Chlamydia trachomatis-induced fallopian tubal fibrosis[J].Mol Cell Biochem,2021,477(1):37-42. [8] 马翠,自辉,薛潇.宫腹腔镜-来曲唑对子宫内膜异位症患者血清炎症因子及ENA-78、MCP-1的影响[J].中南医学科学杂志,2022,50(5):747-749. [9] 刘秋霞,张慧雅.宫-腹腔镜联合来曲唑治疗子宫内膜异位性不孕症的临床效果及对激素水平的影响[J].临床医学研究与实践,2019,4(25):84-85. [10] IRIS H,JOHANNES O,CHRISTINE K, et al. Is chronic endometritis associated with tubal infertility? A prospective cohort study[J].J Minim Invasive Gynecol,2021,28(11):3-6. [11] 吕冬冬.注射用尿促卵泡素联合来曲唑辅助宫腔内人工授精治疗不孕症患者的效果[J].中国民康医学,2022,34(8):46-48. [12] 林子娴,徐俊珊,吴舜彬.来曲唑联合尿促卵泡素治疗克罗米芬抵抗的多囊卵巢综合征不孕患者临床研究[J].基层医学论坛,2021,25(14):1974-1976. [13] 赵海君,张皙卉,陈静,等.三种促排卵方案在高龄合并卵巢储备功能减退不孕症中的应用比较[J].国际生殖健康/计划生育杂志,2023,42(1):13-17. [14] ZHANG L Y,JIANG F X,QI R H, et al. Pregnancy outcomes in patients with tubal infertility following laparoscopic treatment: a multivariate predictive study[J].Ann Palliat Med,2021,10(1):31-36.
2024, Vol. 41 
